Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Next Previous
Trial Profile

Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
  • Indications Amyloid light-chain amyloidosis; Multiple myeloma; Plasmacytoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 20 Aug 2024 Planned End Date changed from 22 Oct 2024 to 27 May 2025.
  • 21 Jul 2023 Planned End Date changed from 22 Oct 2023 to 22 Oct 2024.
  • 11 Jan 2022 Planned End Date changed from 22 Oct 2022 to 22 Oct 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top